S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands
Key facts
- Who runs it
- Dartmouth-Hitchcock Medical Center
- Where
- Lebanon, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 40 people enrolled
- Started
- 17 Aug 2022
- Ended
- 11 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- S-Adenosyl-L-Methionine (Sam-E)
- Placebo
- Record updated
- 16 July 2025
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Current primary care provider within the Dartmouth Health system
- Office visit at Dartmouth Health in the past 3 years
- Participants must be 40 or older at the time of signing the informed consent
- Participants have discomfort or functional limitations of one or both hands AND either:; Objective findings of at least one hand meeting diagnostic criteria based on the American College of Rheumatology (ACR)* or; Existing radiographic evidence of osteoarthritis as judged by a radiologist
- Patients taking OTC or prescription analgesics who are willing to stop their current analgesics for two weeks prior to study entry and remain off those medications over the course of the study
- *Objective inclusion criteria (see poster schematic); Swelling or deformity of 2 of the following ten joints: the 2nd and 3rd distal interphalangeal (DIP) of each hand, the 2nd and 3rd proximal interphalangeal (PIP) of each hand, and the 1st carpometacarpal joints of both hands
Who cannot take part
- Patients taking prescription medications other than NSAIDs for their OA who are unable to stop their medication
- Patients taking any of the following medications at study entry OR starting any of these medications during the study period:; daily opioids (including tramadol or buprenorphine); gabapentin or pregabalin; prednisone; Prescription NSAIDs that they are unable to stop or topical diclofenac; SNRI drugs (Effexor, Cymbalta, Fetzima, Pristiq)
- Patients with diagnoses of arthritis from conditions other than OA
- Patients with Bipolar Disorder
- The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- Patients whose symptomatic joint is an artificial joint
Where in United States
- Dartmouth Hitchcock Medical CenterLebanon, United States
About the trial
What the trial wants to find out
The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.
The 2 groups in the trial
- S-Adenosyl-L-Methionine (SAMe)Treatment being tested
Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
Treatment: S-Adenosyl-L-Methionine (Sam-E) and Placebo
- PlaceboPlacebo, for comparison
Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
Treatment: S-Adenosyl-L-Methionine (Sam-E) and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- S-Adenosyl-L-Methionine (SAMe) vs Placebo for Discomfort and Functional Limitations Associated With Osteoarthritis of the Hands: a Pilot Study
- Record updated
- 16 July 2025